A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
Phase 1
10
about 1.7 years
21–80
1 site in MO
What this study is about
This trial is testing if drug (NIO752) reduces production of tau, a protein that builds up in the brain and causes damage in Alzheimer's disease. The goal is to see if NIO752 can help slow down this process.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take NIO752
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Secondary: Compare rates of tau synthesis and clearance in sporadic AD and ADAD, Comparison of number of Adverse Events reported between participants receiving one dose of NIO752 versus those receiving two doses of NIO752., Number of participants with adverse events [safety and tolerability]
Neurology